Search icon

MICROSTRUCTURE IMAGING, INC.

Company Details

Name: MICROSTRUCTURE IMAGING, INC.
Jurisdiction: New York
Legal type: FOREIGN BUSINESS CORPORATION
Status: Active
Date of registration: 09 Jul 2018 (7 years ago)
Entity Number: 5372063
ZIP code: 10036
County: New York
Place of Formation: Delaware
Address: 1177 AVENUE OF THE AMERICAS, 7TH FLOOR/ATELIER, NEW YORK, NY, United States, 10036

DOS Process Agent

Name Role Address
THE CORPORATION DOS Process Agent 1177 AVENUE OF THE AMERICAS, 7TH FLOOR/ATELIER, NEW YORK, NY, United States, 10036

U.S. Small Business Administration Profile

The U.S. Small Business Administration (SBA) helps Americans start, grow, and build resilient businesses.

Note: SBA was created in 1953 as an independent agency of the federal government to aid, counsel, assist and protect the interests of small business concerns; preserve free competitive enterprise; and maintain and strengthen the overall economy of our nation. SBA reviews Congressional and testifies on behalf of small businesses. It assesses the impact of regulatory burden on small businesses.

Phone Number:
Contact Person:
GREGORY LEMBERSKIY
User ID:
P2784673

Filings

Filing Number Date Filed Type Effective Date
180709000377 2018-07-09 APPLICATION OF AUTHORITY 2018-07-09

USAspending Awards / Financial Assistance

Date:
2024-09-09
Awarding Agency Name:
Department of Health and Human Services
Transaction Description:
REPORTING QUANTITATIVE MICROSTRUCTURAL MRI METRICS TO STAGE AND MONITOR MULTIPLE SCLEROSIS - PROJECT SUMMARY AT LEAST 400,000 PEOPLE IN THE UNITED STATES ARE AFFECTED BY MULTIPLE SCLEROSIS (MS), WHICH IS THE MOST PREVALENT CHRONIC INFLAMMATORY DISEASE OF THE CENTRAL NERVOUS SYSTEM (CNS). THE CURRENT NON-INVASIVE MRI GOLD-STANDARD OF MS CHARACTERIZATION IS THROUGH VOLUMETRIC BIOMARKERS, PRIMARILY CHARACTERIZING LESION LOAD (NUMBER AND VOLUME OF LESIONS), OR BRAIN VOLUME ATROPHY (WHICH IS ACCELERATED IN MS BRAINS). HOWEVER, VOLUME LOSS ASSOCIATED WITH UNDERLYING NEURODEGENERATION IN MS OVER A 6-12 MONTH PERIOD, WHILE ABNORMAL, MAY STILL BE LESS THAN THE PRECISION OF THE VOLUMETRIC MEASUREMENT, SUCH THAT VOLUME CHANGES IN INDIVIDUAL MS PATIENTS MAY ONLY BE CONFIDENTLY DIAGNOSED OVER 18-24 MONTHS AND BASED ON MULTIPLE MEASUREMENTS. THE VOLUMETRIC MEASUREMENT ALSO IS MOST VALID AND PRECISE ONLY WHEN OBTAINED ON THE SAME MRI SCANNER EACH TIME, WHICH IS OFTEN IMPRACTICAL IN THE CURRENT US HEALTHCARE ENVIRONMENT. OUR APPROACH IS TO DERIVE QUANTITATIVE MRI BIOMARKERS FROM DIFFUSION MRI (DMRI), WHICH DESCRIBE PROPERTIES OF THE MICROSCOPIC ENVIRONMENT AND HAS BEEN SHOWN TO OUTPERFORM VOLUMETRICS. THERE HAS BEEN A GLOBAL EFFORT TO REPARAMETRIZE THE WM DMRI SIGNAL, THROUGH THE STANDARD MODEL (SMI) OF WHITE MATTER, AS THE SUMMATION OF TISSUE COMPARTMENTS TYPICALLY OVER INTRA-AXONAL, EXTRA-AXONAL AND FREE-WATER COMPARTMENTS, ENABLING DISENTANGLING INFLAMMATORY AND DEGENERATIVE PROCESSES. AIM 1. CURATE DATABASE OF AGE- AND SEX-MATCHED NORMATIVE REFERENCE SMI PARAMETERS. IN COLLABORATION WITH NYU’S MULTIPLE SCLEROSIS COMPREHENSIVE CENTER (MSCC), WE WILL RETROSPECTIVELY REPROCESS MULTI-SHELL DMRI DATA IN ADULT POPULATIONS FOR NORMAL (N=544) AND MS (N=418) PATIENTS TO DEFINE CLINICALLY RELEVANT SMI RANGES. AIM 2. DEVELOP A SOFTWARE PLATFORM TO AUTOMATE BIOMARKER ANALYSIS. USING DATA FROM AIM 1, AN FDA- COMPLIANT BACKEND SOFTWARE PIPELINE PERFORMING IMAGE PROCESSING, STATISTICAL COMPARISONS AND END-USER REPORTING WILL BE DEVELOPED IN PYTHON AND CONTAINERIZED FOR CROSS-PLATFORM GENERALIZATION. THE END-PRODUCT IS THE MS-MICSI REPORT TO AID CLINICIANS IN PROGNOSTIC DECISION MAKING AND INFORM PHARMACEUTICAL DRUG TRIALS. AIM 3. VERIFICATION AND VALIDATION OF THE MS-MICSI REPORT WILL BE PERFORMED ON (A) 15 HEALTHY VOLUNTEERS, (B) 40 MS PATIENTS, 15 OF WHICH WILL RETURN FOR A FOLLOW-UP IN 9 MONTHS TO BE IMAGED, AND (C) SCAN-RESCAN (N=20 AGE/SEX MATCHED HEALTHY VOLUNTEERS) TO EVALUATE BIAS AND PRECISION OF SMI PARAMETERS. CROSS SECTIONAL AND LONGITUDINAL CHANGES OBSERVED BY MS-MICSI WILL BE COMPARED AGAINST COMMERCIALLY AVAILABLE VOLUMETRICS.
Obligated Amount:
353942.00
Face Value Of Loan:
0.00
Total Face Value Of Loan:
0.00
Date:
2021-09-28
Awarding Agency Name:
Department of Health and Human Services
Transaction Description:
NON-INVASIVE NEUROSURGICAL PLANNING WITH RANDOM MATRIX THEORY MRI - PROJECT SUMMARY THIS APPLICATION IS INTENDED FOR I-CORPS AT NIH. SUMMARY OF THE ASSOCIATED NIH NCI STTR PHASE I ABOUT 23,830 PEOPLE IN THE US ARE DIAGNOSED PER YEAR WITH PRIMARY MALIGNANT BRAIN TUMORS, AND 200,000- 300,000 WITH METASTATIC BRAIN TUMORS (10-30% OF ALL CANCERS). MAXIMIZING SURGICAL RESECTION OF TUMOR IS A MAJOR PREDICTOR OF SURVIVAL, BUT MUST BE BALANCED AGAINST THE RISK OF INJURING ELOQUENT WHITE MATTER AND CORTICAL REGIONS. TO IMPROVE OUTCOMES, THE UNMET NEED IS TO RADICALLY INCREASE QUALITY OF NONINVASIVE PREOPERATIVE BRAIN MAPPING. AS THE BRAIN MAPPING GOLD STANDARD, MRI OFFERS UNIQUE SOFT-TISSUE CONTRAST, ANATOMICAL AND FUNCTIONAL INFORMATION OF THE BRAIN, YET IS INHERENTLY SIGNAL-TO-NOISE RATIO (SNR)-STARVED. THE MAJORITY OF BRAIN MAPPING RELIES ON DIFFUSION (DMRI) AND FUNCTIONAL (FMRI), WHICH ARE BOTH ESPECIALLY SEVERELY LIMITED BY SNR. THE MRI SIGNAL CAN BE INCREASED WITH HIGHER-FIELD; HOWEVER, SCANNER PRICES SCALE WITH THE FIELD STRENGTH: 1.5T ~ $1.5M, 7T ~ $7M, AS DO INSTALLATION AND SERVICE COSTS. SINCE 90% OF THE MRIS IN THE US ARE 1.5T OR BELOW, IT APPEARS THAT THE MAJORITY OF HOSPITALS CANNOT JUSTIFY OR AFFORD HIGH FIELD MRI. SNR INCREASE BY THE SIGNAL AVERAGING IS IMPRACTICAL FROM THE SCAN TIME PERSPECTIVE, AS BRAIN TUMOR PATIENTS RARELY TOLERATE SCAN TIMES ABOVE 45 MIN. OUR COMPANY, MICROSTRUCTURE IMAGING (MICSI), IS AN AWARD-WINNING NEW YORK UNIVERSITY (NYU) SPINOFF THAT OFFERS A SOFTWARE-AS-A-SERVICE FOR MEDICAL IMAGE PROCESSING. OUR PRODUCT DRAMATICALLY ENHANCES THE SNR OF MRI BRAIN MAPPING, WHICH TRANSLATES INTO INCREASED RESOLUTION, IMAGE QUALITY, SENSITIVITY AND SPECIFICITY. HERE WE EMPLOY RANDOM MATRIX THEORY (RMT) TO ACHIEVE AN ORDER-OF-MAGNITUDE GAIN IN SNR PURELY IN SOFTWARE AT THE IMAGE RECONSTRUCTION LEVEL, BY UTILIZING THE INFORMATION ACROSS MULTIPLE RADIOFREQUENCY COILS AND MRI CONTRASTS WITHIN A SINGLE PROTOCOL. OUR OVERARCHING GOAL IS TO OPTIMIZE OUR RMT/MP-PCA IMAGE RECONSTRUCTION ALGORITHM FOR THE CLINICAL TRANSLATION IN BRAIN MAPPING PREOPERATIVE STUDIES. OUR SPECIFIC AIMS ARE: AIM 1: ENABLING LOWER FIELD / HIGHER RESOLUTION. WE WILL DEVELOP AND EVALUATE A MULTIMODAL (DMRI/FMRI) RMT DENOISING AND RECONSTRUCTION PROTOCOL IN 6 VOLUNTEERS ON 1.5T AND 3T WITH DIFFERENT IMAGE RESOLUTIONS, AND RETROSPECTIVELY IN 30 PREOPERATIVE BRAIN MAPPING MRI PATIENTS. THIS DATA WILL BE USED TO JUSTIFY PROSPECTIVELY ALTERING CLINICAL MRI PROTOCOLS DURING THE ANTICIPATED PHASE II OF THE STTR. AIM 2: CLINICAL FEASIBILITY STUDY. 15 MINUTES OF ADDITIONAL SCAN TIME FOR DMRI AND 2 FMRI TASKS AT 1.2 MM ISOTROPIC RESOLUTION WILL BE PROSPECTIVELY ADDED TO 10 BRAIN MAPPING CASES AT 3T. THE IMAGE QUALITY WITH AND WITHOUT DENOISING WILL BE ASSESSED QUANTITATIVELY, AND QUALITATIVELY BY RADIOLOGISTS AND NEUROSURGEONS. WHILE THE PHASE-I STTR WILL OPTIMIZE RMT IN PREOPERATIVE PLANNING FOR BRAIN TUMORS, IN THE FUTURE WE WILL OPTIMIZE PROTOCOLS FOR ANY TUMOR TYPE OR LOCATION BY JOINT RMT RECONSTRUCTION OF VARIETY OF MRI MODALITIES (PERFUSION, T1/T2, DMRI, FMRI) TO HELP THEM DENOISE EACH OTHER AND MAXIMIZE THE OVERALL INFORMATION CONTENT. RMT IMAGE RECONSTRUCTION WILL OPEN MRI TO THE DEVELOPING WORLD BY BRINGING HIGH-FIELD QUALITY TO INEXPENSIVE LOW-FIELD MRI.
Obligated Amount:
454999.00
Face Value Of Loan:
0.00
Total Face Value Of Loan:
0.00

Date of last update: 23 Mar 2025

Sources: New York Secretary of State